Long-term treatment with idebenone and riboflavin in a patient with MELAS

Neurol Sci. 2000;21(5 Suppl):S981-2. doi: 10.1007/s100720070015.

Abstract

We report a patient with MELAS treated for 24 months with idebenone and riboflavin, during which no stroke-like episodes occurred. Moreover neurological symptoms clearly improved, and a recovery of brain MRI and EEG abnormalities was observed. We conclude that the combined treatment with idebenone and riboflavin may restore the metabolic impairment in MELAS, possibly improving the long-term prognosis in these patients.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antioxidants / pharmacology*
  • Aphasia, Wernicke / drug therapy
  • Aphasia, Wernicke / etiology
  • Aphasia, Wernicke / pathology
  • Benzoquinones / pharmacology*
  • Cerebral Cortex / pathology
  • Cerebral Cortex / physiopathology
  • Cerebral Infarction / drug therapy
  • Cerebral Infarction / etiology
  • Cerebral Infarction / pathology
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Electron Transport / drug effects
  • Electron Transport / genetics
  • Humans
  • MELAS Syndrome / complications
  • MELAS Syndrome / drug therapy*
  • MELAS Syndrome / physiopathology
  • Magnetic Resonance Imaging
  • Male
  • Mitochondria / drug effects
  • Mitochondria / genetics
  • Mitochondria / metabolism
  • Photosensitizing Agents / pharmacology*
  • Riboflavin / pharmacology*
  • Treatment Outcome
  • Ubiquinone / analogs & derivatives

Substances

  • Antioxidants
  • Benzoquinones
  • Photosensitizing Agents
  • Ubiquinone
  • idebenone
  • Riboflavin